A Study of Tirzepatide (LY3298176) in Chinese Participants With Type 2 Diabetes (SURPASS-CN-MONO)

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 206 participants.

Also called NCT05963022

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 206 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT05963022
Other papers using this trial's data
  • Tirzepatide monotherapy in Chinese patients with early type 2 diabetes: A randomized, double-blind, placebo-controlled phase 3 trial (SURPASS-CN-MONO) Med (New York, N.Y.), 2026-07-10 DOI, PubMed 42296968

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
China (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT05963022. Randomized; double masking; primary purpose treatment. Start 2023-08-21 (actual); primary completion 2024-10-09 (actual). Results posted on 2025-10-21.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study of Tirzepatide (LY3298176) in Chinese Participants With Type 2 Diabetes (SURPASS-CN-MONO)
Intervention (Drug)
Tirzepatide
Intervention (Drug)
Placebo
Lead sponsor
Eli Lilly and Company (class: industry)

Record details

Record id
cardio:ct-nct05963022
Content hash
115c2a6830fa34b558b4727eeba3b6c89ce622a327c03e2127d837e3b4ca53b2